Literature DB >> 26113173

Comment on "Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study".

Florenzo Iannone1, Elisa Gremese2, Gianfranco Ferraccioli3, Giovanni Lapadula4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26113173     DOI： 10.1007/s10067-015-2997-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  3 in total

1.  Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.

Authors:  Ko-Ming Lin; Tien-Tsai Cheng; Jing-Chi Lin; Chung-Jen Chen
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.

Authors:  Florenzo Iannone; Giovanni La Montagna; Gianfilippo Bagnato; Elisa Gremese; Annarita Giardina; Giovanni Lapadula
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.